X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs TORRENT PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD TORRENT PHARMA WYETH LTD/
TORRENT PHARMA
 
P/E (TTM) x 27.7 44.4 62.4% View Chart
P/BV x 5.3 6.3 85.3% View Chart
Dividend Yield % 1.3 0.8 155.9%  

Financials

 WYETH LTD   TORRENT PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
TORRENT PHARMA
Mar-18
WYETH LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0441,550 67.4%   
Low Rs8181,144 71.5%   
Sales per share (Unadj.) Rs298.6354.7 84.2%  
Earnings per share (Unadj.) Rs57.240.1 142.8%  
Cash flow per share (Unadj.) Rs58.464.2 91.0%  
Dividends per share (Unadj.) Rs17.0014.00 121.4%  
Dividend yield (eoy) %1.81.0 175.6%  
Book value per share (Unadj.) Rs249.5273.1 91.3%  
Shares outstanding (eoy) m22.72169.22 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.8 82.1%   
Avg P/E ratio x16.333.6 48.4%  
P/CF ratio (eoy) x15.921.0 76.0%  
Price / Book Value ratio x3.74.9 75.7%  
Dividend payout %29.734.9 85.0%   
Avg Mkt Cap Rs m21,157227,897 9.3%   
No. of employees `0000.514.7 3.3%   
Total wages/salary Rs m40011,353 3.5%   
Avg. sales/employee Rs Th13,787.44,083.0 337.7%   
Avg. wages/employee Rs Th813.0772.3 105.3%   
Avg. net profit/employee Rs Th2,643.3461.3 573.0%   
INCOME DATA
Net Sales Rs m6,78360,021 11.3%  
Other income Rs m3532,988 11.8%   
Total revenues Rs m7,13663,009 11.3%   
Gross profit Rs m1,61713,493 12.0%  
Depreciation Rs m274,086 0.7%   
Interest Rs m63,085 0.2%   
Profit before tax Rs m1,9389,310 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6322,529 25.0%   
Profit after tax Rs m1,3016,781 19.2%  
Gross profit margin %23.822.5 106.1%  
Effective tax rate %32.627.2 120.1%   
Net profit margin %19.211.3 169.7%  
BALANCE SHEET DATA
Current assets Rs m6,98452,623 13.3%   
Current liabilities Rs m2,05652,022 4.0%   
Net working cap to sales %72.61.0 7,249.2%  
Current ratio x3.41.0 335.8%  
Inventory Days Days99120 83.0%  
Debtors Days Days2476 31.4%  
Net fixed assets Rs m24485,016 0.3%   
Share capital Rs m227846 26.8%   
"Free" reserves Rs m5,44145,376 12.0%   
Net worth Rs m5,66846,222 12.3%   
Long term debt Rs m2541,115 0.1%   
Total assets Rs m7,901142,432 5.5%  
Interest coverage x353.34.0 8,793.5%   
Debt to equity ratio x00.9 0.5%  
Sales to assets ratio x0.90.4 203.7%   
Return on assets %16.56.9 238.6%  
Return on equity %22.914.7 156.4%  
Return on capital %34.014.2 239.9%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1514,580 0.1%   
Fx outflow Rs m2,6773,600 74.4%   
Net fx Rs m-2,66210,980 -24.2%   
CASH FLOW
From Operations Rs m9238,942 10.3%  
From Investments Rs m317-47,070 -0.7%  
From Financial Activity Rs m-48134,174 -1.4%  
Net Cashflow Rs m759-3,655 -20.8%  

Share Holding

Indian Promoters % 0.0 71.5 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 7.0 161.0%  
FIIs % 7.2 12.6 57.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 8.8 345.5%  
Shareholders   21,978 26,511 82.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ABBOTT INDIA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS